CAJ | 학술논문

目的:主要探讨胰岛素强化治疗对2型糖尿病磺脲类继发失效患者的疗效.方法:磺脲类继发失效患者21例.停用原口服药后予以胰岛素强化治疗,疗程2周.检测治疗前后的糖代谢参数,并以此计算B细胞分泌功能和胰岛素抵抗状况等.结果:胰岛素强化治疗后血糖达标时间平均为(4.4±2.1)d,胰岛素剂量平均为(48.9±19.5)U/d,未出现明显不良反应.与治疗前比较,治疗后B细胞分泌功能显著改善(P<0.05或P<0.01),胰岛素抵抗指数亦有改善(P<0.05).结论:胰岛素强化治疗,对磺脲类继发性失效患者有较好的疗效.
목적:주요탐토이도소강화치료대2형당뇨병광뇨류계발실효환자적료효.방법:광뇨류계발실효환자21례.정용원구복약후여이이도소강화치료,료정2주.검측치료전후적당대사삼수,병이차계산B세포분비공능화이도소저항상황등.결과:이도소강화치료후혈당체표시간평균위(4.4±2.1)d,이도소제량평균위(48.9±19.5)U/d,미출현명현불량반응.여치료전비교,치료후B세포분비공능현저개선(P<0.05혹P<0.01),이도소저항지수역유개선(P<0.05).결론:이도소강화치료,대광뇨류계발성실효환자유교호적료효.
Objective: To discuss intensive insulin therapy for type 2 diabetes with secondary sulfonylurea failure patients. Methods: Patients with secondary sulfonylurea failure in 21 eases had stopped using the original oral and received inten-sive insulin therapy, 2 weeks treatment. Before and after treatment by tested the glucose metabolism parameters, and cal-culated B-cell secretory function and insulin resistance status. Results: Intensive insulin therapy after the average of blood glucose target (4.4±2.1) d, insulin dose averaged (48.9±19.5) U/d, there was no significant adverse reactions. Compared with before treatment, after treatment of B-cell secretory function improved significantly (P<0.05 or P<0.01), insulin resis-tance index also improved (P><0.05). Conclusion: Intensive insulin has better efficacy in patients with secondary failure of sulfonylurea efficacy.